Serum endothelial monocyte-activating polypeptide-II: a novel biomarker in patients with non-small-cell lung cancer.

@article{en2008SerumEM,
  title={Serum endothelial monocyte-activating polypeptide-II: a novel biomarker in patients with non-small-cell lung cancer.},
  author={Elif Hilal Şen and Fusun Ulger and Akin Kaya and Nejat Akar and Ugur Gonullu},
  journal={Clinical lung cancer},
  year={2008},
  volume={9 3},
  pages={166-70}
}
BACKGROUND Endothelial monocyte-activating polypeptide-II (EMAP-II) is a proinflammatory cytokine with antiangiogenic properties. Serum EMAP-II levels have not been investigated previously in non-small-cell lung cancer (NSCLC). The aim of this study was to examine the relationship between serum EMAP-II levels and clinicopathologic features, including prognosis, in patients with NSCLC. PATIENTS AND METHODS We measured serum EMAP-II levels in 30 healthy control subjects and 48 patients with… CONTINUE READING
2 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…